NQO1 (NAD(P)H:quinone oxidoreductase 1) is a Phase II detoxification enzyme¹¹ Phase II detoxification enzyme
Phase II enzymes conjugate or reduce reactive metabolites produced by Phase I enzymes, making them safer and easier to excrete that performs an unusual and critically important reaction: it reduces toxic quinones directly to stable hydroquinones via a two-electron transfer, completely bypassing the dangerous one-electron semiquinone radical²² semiquinone radical
A partially reduced quinone that reacts with oxygen to generate superoxide and other reactive oxygen species (ROS), causing oxidative damage to DNA, proteins, and lipids intermediate. This makes NQO1 a uniquely efficient detoxifier of quinone compounds, which arise from the metabolism of benzene, environmental pollutants, certain drugs, and normal cellular processes.

Beyond detoxification, NQO1 plays a second major role: it is one of the primary enzymes responsible for reducing CoQ10 (ubiquinone) to its active antioxidant form, ubiquinol. Researchers have proposed that NQO1 was selected during evolution primarily as a CoQ reductase³³ NQO1 was selected during evolution primarily as a CoQ reductase
Ross & Siegel 2017, Functions of NQO1 in Cellular Protection and CoQ10 Metabolism, and that its ability to detoxify xenobiotic quinones was a secondary gain of function. NQO1 also stabilizes the tumor suppressor proteins p53 and p73, protecting them from proteasomal degradation.

The rs1800566 variant (C609T in cDNA) causes a proline-to-serine substitution at position 187, falling in a region critical for the binding of the FAD cofactor⁴⁴ FAD cofactor
Flavin adenine dinucleotide, the essential cofactor that NQO1 requires to catalyze electron transfer reactions. This single amino acid change has dramatic consequences for protein stability and enzyme function.

The Mechanism

The Pro187Ser substitution disrupts the structural integrity of the NQO1 protein in a way that is unusually severe for a single missense variant. The serine at position 187 destabilizes the protein's tertiary structure, particularly at the FAD binding site in the N-terminal domain and the C-terminal domain important for substrate binding. The mutant protein is rapidly polyubiquitinated and degraded by the proteasome⁵⁵ rapidly polyubiquitinated and degraded by the proteasome
Siegel et al. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol, 2001, resulting in dramatically reduced intracellular NQO1 levels.

Heterozygotes (AG genotype, one variant copy) retain approximately one-third of normal enzyme activity. Homozygotes (AA genotype, two variant copies) retain only 2-4% of wild-type activity -- essentially no functional NQO1. This is because the mutant protein is so unstable that it is degraded almost as fast as it is made.

Without functional NQO1, quinone metabolism shifts to the one-electron pathway via cytochrome P450 reductase, generating reactive semiquinone radicals that produce superoxide, hydrogen peroxide, and hydroxyl radicals through redox cycling⁶⁶ redox cycling
A process where a molecule is repeatedly reduced and then re-oxidized by oxygen, generating a continuous stream of reactive oxygen species with each cycle. This increases oxidative stress and, in the context of benzene exposure, explains the heightened vulnerability to hematotoxicity.

The Evidence

Protein stability and activity: The foundational work by Siegel et al.⁷⁷ Siegel et al.
Siegel D et al. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol, 2001 demonstrated that while wild-type NQO1 persists in cells, the Pro187Ser mutant is rapidly ubiquitinated and sent to the proteasome for degradation. This elegant study explained why TT homozygotes have near-zero enzyme activity despite normal gene transcription.

Benzene toxicity: The NQO1-benzene connection was established in a landmark study of Chinese workers by Rothman et al.⁸⁸ Rothman et al.
Rothman N et al. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C>T mutation. Cancer Res, 1997, who found a 7.6-fold increased risk of benzene poisoning in workers carrying the TT genotype combined with CYP2E1 rapid metabolizer status. A subsequent PNAS study showed that TT homozygotes cannot induce NQO1 in response to hydroquinone exposure⁹⁹ cannot induce NQO1 in response to hydroquinone exposure
Moran JL, Siegel D, Ross D. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NQO1 to benzene toxicity. PNAS, 1999, leaving them unable to mount the normal protective enzyme response. Further studies in benzene-exposed workers found that those with the TT genotype who smoked or drank alcohol had 8- to 21-fold increased risk of benzene poisoning¹⁰¹⁰ 8- to 21-fold increased risk of benzene poisoning
Wan J et al. Association of genetic polymorphisms in CYP2E1, MPO, NQO1, GSTM1, and GSTT1 genes with benzene poisoning. Environ Health Perspect, 2002.

Cancer risk: A comprehensive meta-analysis of 92 studies encompassing 21,178 cases and 25,157 controls¹¹¹¹ 92 studies encompassing 21,178 cases and 25,157 controls
Lajin B, Alachkar A. The NQO1 polymorphism C609T and cancer susceptibility: a comprehensive meta-analysis. Br J Cancer, 2013 found a statistically significant association between the TT genotype and overall cancer risk (OR 1.18, 95% CI 1.07-1.31). The strongest association was with bladder cancer (TT vs CC: OR 1.70, 95% CI 1.17-2.46). Notably, the association was more pronounced in Caucasian populations (OR 1.28) than in Asian populations, despite the much higher variant frequency in East Asians.

Breast cancer and chemotherapy: A Nature Genetics study¹²¹² Nature Genetics study
Fagerholm R et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet, 2008 found that NQO1*2 homozygosity strongly predicted poor survival in two independent series of breast cancer patients, with the effect particularly evident after anthracycline-based chemotherapy. This reflects NQO1's dual role in drug activation and p53 stabilization.

CoQ10 recycling: NQO1 is one of at least five enzyme systems that reduce ubiquinone to its active antioxidant form, ubiquinol. In individuals lacking functional NQO1, this recycling pathway is impaired. Preliminary evidence suggests that plasma CoQ10 levels may be lower in NQO1*2 carriers¹³¹³ plasma CoQ10 levels may be lower in NQO1*2 carriers
Ross D, Siegel D. Functions of NQO1 in Cellular Protection and CoQ10 Metabolism. Front Physiol, 2017, though larger confirmatory studies are needed.

Practical Implications

The TT (AA) genotype is especially relevant for individuals with occupational chemical exposures, those undergoing chemotherapy, and anyone interested in optimizing antioxidant status. Key considerations:

Chemical exposures: Individuals with the AA genotype should be particularly cautious about benzene and quinone-generating compound exposure. Benzene is found in gasoline, industrial solvents, and cigarette smoke. Minimizing exposure is more important when your body cannot efficiently detoxify the resulting quinone metabolites.

CoQ10 supplementation: Because NQO1 is one of the major enzymes that recycles CoQ10 from its oxidized (ubiquinone) to its reduced (ubiquinol) form, individuals with impaired NQO1 activity should use the ubiquinol form of CoQ10 rather than ubiquinone, as they may have reduced capacity to make this conversion themselves.

Antioxidant support: Without efficient quinone detoxification, the body experiences higher baseline oxidative stress. Supporting other antioxidant pathways -- through diet rich in colorful fruits and vegetables, and adequate selenium, vitamin C, and vitamin E -- becomes more important.

Oncology relevance: The NQO1 genotype may be relevant for chemotherapy drug selection, particularly for quinone-based agents and anthracyclines. This is an area of active research and should be discussed with an oncologist if relevant.

Interactions

NQO1 interacts with other Phase II detoxification and antioxidant enzymes. SOD2 (rs4880) converts superoxide to hydrogen peroxide, while NQO1 prevents superoxide generation in the first place by bypassing the semiquinone step. When both NQO1 and SOD2 are impaired, oxidative stress burden compounds -- NQO1 deficiency allows more superoxide generation, and SOD2 variants reduce the capacity to neutralize it.

GSTP1 (rs1695) is another Phase II enzyme that conjugates reactive metabolites with glutathione. Combined impairment of NQO1 and GSTP1 may further reduce the body's capacity to handle quinone toxicity and electrophilic compounds.

GPX1 (rs1050450) encodes glutathione peroxidase 1, which neutralizes hydrogen peroxide. In combination with NQO1 loss, reduced GPX1 activity creates a situation where both the generation of reactive oxygen species (via quinone redox cycling) and their clearance (via peroxide reduction) are compromised.

The combined effect of NQO1 TT with CYP2E1 rapid metabolizer status on benzene toxicity is well-documented: CYP2E1 rapidly converts benzene to quinone metabolites while NQO1 deficiency prevents their safe detoxification, creating a metabolic funnel toward toxicity.

CYP1A2 is the liver enzyme responsible for breaking down roughly 95% of caffeine, as well as several important medications including clozapine, theophylline, and escitalopram. The enzyme's activity varies substantially between individuals — up to 40-fold — driven by a combination of genetic polymorphisms, smoking status, and dietary factors. The rs2069526 variant (-739T>G) is an intronic change located near the 5' end of CYP1A2 ¹¹ HGVS: NM_000761.5:c.-10+103T>G; chromosome 15, GRCh38 position 74,748,999. Its G allele is rare globally (approximately 5–7%) and has been associated with differences in how certain CYP1A2 substrates are cleared, though its independent functional effect remains less clearly established than the better-studied rs762551 (*1F) variant.

The Mechanism

As an intronic variant, rs2069526 does not alter the amino acid sequence of the CYP1A2 protein. Instead, it may influence ²² gene expression: how much of the enzyme protein is made in liver cells or splicing efficiency. Intronic variants near exon-intron boundaries or regulatory regions can create or disrupt binding sites for splicing factors or transcription regulators. The -739 position places this variant upstream of the main coding region, where it could modulate basal or inducible transcription in conjunction with other haplotype-defining SNPs.

The Evidence

A pharmacogenomics study of 158 Taiwanese patients receiving escitalopram³³ pharmacogenomics study of 158 Taiwanese patients receiving escitalopram
Kuo HW et al. CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions. Pharmacogenomics, 2013 found that rs2069526 was significantly associated with the S-DDCIT/S-DCIT metabolic ratio at week 2 (p = 0.018). Individuals with G alleles — which correlated with elevated metabolic ratios — experienced more pronounced adverse effects early in treatment. Notably, CYP2C19 is the primary pathway for escitalopram; this finding suggests rs2069526 may tag a CYP1A2 haplotype that modulates a secondary metabolic route or reflects linkage disequilibrium with a functionally important variant.

A meta-analysis of lung cancer risk⁴⁴ meta-analysis of lung cancer risk
Bu ZB et al. Four polymorphisms in CYP1A2 and lung cancer risk: a meta-analysis. Asian Pac J Cancer Prev, 2014 pooled five studies (657 cases, 984 controls) and found no significant association between rs2069526 and lung cancer risk. A Swedish-Korean comparison study⁵⁵ Swedish-Korean comparison study
Ghotbi R et al. CYP1A2 genetic polymorphisms, enzyme activity and genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol, 2007 found no significant genotype-phenotype relationship for the -739T>G variant alone, while confirming that the related rs762551 (*1F) allele was associated with higher enzyme inducibility in smokers. Together, the evidence suggests rs2069526 may have limited independent functional significance but could be part of a haplotype block tagging broader CYP1A2 activity differences.

Practical Actions

Because this variant is in the same gene as the well-characterized rs762551 (*1F), individuals carrying the G allele at rs2069526 should be aware that CYP1A2 activity in their case remains less predictable from this single variant alone. For medications processed primarily by CYP1A2 — particularly clozapine, theophylline, and tizanidine — therapeutic drug monitoring is the most reliable approach rather than genotype-directed dosing from this marker alone. Smoking is the dominant environmental regulator of CYP1A2 and can increase enzyme activity by two- to three-fold, outweighing most genetic effects; changes in smoking status during CYP1A2-substrate treatment require dose re-evaluation.

Interactions

rs2069526 was found to be significantly associated with escitalopram metabolic ratios in the same study that identified rs2069521 and rs4646425 (Kuo et al., 2013). These variants may act in concert as a haplotype, meaning the observed escitalopram association may reflect combined haplotype effects rather than the action of rs2069526 in isolation. The rs762551 (*1F) variant at the same locus has substantially stronger and better-replicated evidence for affecting CYP1A2 inducibility, caffeine clearance, and cardiovascular risk from coffee.

The ESR1 gene encodes estrogen receptor alpha (ERα), one of two primary mediators through which estrogen exerts its effects on bone, cardiovascular, and reproductive tissues. This intron 1 variant (also called PvuII or -397T>C) lies 397 base pairs upstream of exon 2¹¹ 397 base pairs upstream of exon 2
located in a regulatory region that may affect transcription factor binding and has been extensively studied for associations with bone density, fracture risk, cardiovascular disease, and hormone therapy response²² extensively studied for associations with bone density, fracture risk, cardiovascular disease, and hormone therapy response
over 255 publications have examined this variant.

The Mechanism

The PvuII polymorphism involves a T to C transition in intron 1 that may affect transcription factor binding, potentially altering protein expression of the ESR1 gene . While the variant does not change the amino acid sequence, its location in a regulatory element suggests it influences how much estrogen receptor alpha is produced or how efficiently it responds to estrogen signaling.

The variant is on the plus strand, with T as the reference allele and C as the alternate .

The Evidence

The evidence for this variant's effects has been mixed and context-dependent. A large European meta-analysis of 18,917 individuals³³ A large European meta-analysis of 18,917 individuals
Ioannidis et al., JAMA 2004 found that none of the ESR1 polymorphisms including PvuII had any statistically significant effect on bone mineral density, yet significant reductions in fracture risk were observed . This suggests

ESR1 determines fracture risk by mechanisms independent of BMD .

More recent findings are nuanced by ancestry.

A meta-analysis revealed that the PvuII T allele is a highly significant risk factor for hip fracture susceptibility, with an effect magnitude similar in male and pre-menopausal and post-menopausal female patients . However, when credibility was evaluated applying false-positive reporting probability and Bayesian criteria, significant associations were considered as false positive results , suggesting the need for cautious interpretation.

For muscle health, the C allele provides protection against muscle injury by lowering muscle stiffness in a study of 1,311 Japanese top-level athletes⁴⁴ study of 1,311 Japanese top-level athletes
Kumagai et al., Medicine & Science in Sports & Exercise 2019.

Cardiovascular associations remain controversial.

A large Danish study found ESR1 IVS1-397T/C polymorphism does not influence HDL cholesterol response to hormone replacement therapy or risk of cardiovascular disease . Yet when combined with the XbaI variant (rs9340799), haplotype analysis revealed that C-G haplotype confers approximately 5-fold risk and T-A haplotype adds 1.4-fold risk towards coronary artery disease .

Practical Implications

The most actionable finding relates to hormone therapy response. A study of 343 Slovak postmenopausal women⁵⁵ A study of 343 Slovak postmenopausal women
Mondockova et al., BMC Medical Genetics 2018 found that

TT genotype responded more poorly to hormone therapy and raloxifene in lumbar spine BMD compared to TC and CC genotypes . This suggests women with the TT genotype may need closer monitoring or higher doses of estrogen-based therapies.

For fracture risk, the evidence suggests TT individuals should prioritize bone health through weight-bearing exercise, adequate calcium and vitamin D intake, and regular bone density screening, particularly after menopause when estrogen levels decline naturally.

Interactions

This variant is commonly studied alongside the XbaI variant (rs9340799), also in ESR1 intron 1. The two SNPs are in linkage disequilibrium and often analyzed as haplotypes. Studies show the combined effect differs from either variant alone, particularly for cardiovascular disease risk where the C-G haplotype (rs2234693 C paired with rs9340799 G) confers substantially higher CAD risk than would be predicted from either variant independently. Additionally, interactions with MTHFR variants (rs1801133) have been documented in cardiovascular contexts.

PPARGC1A encodes PGC-1alpha¹¹ PGC-1alpha
peroxisome proliferator-activated receptor gamma coactivator 1-alpha: the master transcriptional coactivator controlling mitochondrial biogenesis, fat oxidation, and adaptive thermogenesis. If PPARG is the nuclear receptor that controls adipocyte differentiation, PGC-1alpha is the coactivator that powers the engine running those processes. Every time your cells build new mitochondria — after endurance training, during cold exposure, in response to caloric restriction — PGC-1alpha orchestrates the gene expression program that makes it happen. rs2279525 sits in the 3' untranslated region of PPARGC1A, a regulatory zone that controls how much of the gene's mRNA survives to be translated into protein.

The Mechanism

The 3' untranslated region (3' UTR) of a gene does not encode protein, but it is far from inert. This region contains binding sites for microRNAs²² microRNAs
miRNAs are short non-coding RNAs that bind to complementary sequences in the 3' UTR and either block translation or trigger mRNA degradation, allowing cells to fine-tune protein output post-transcriptionally and RNA-binding proteins that collectively determine how stable the mRNA is and how efficiently it is translated. Variants in 3' UTRs that alter these binding sites can shift the setpoint of protein production without changing the protein itself.

rs2279525 is a T>C substitution at GRCh38 position chr4:23,792,629, within the 3' UTR of multiple PPARGC1A transcript variants. PPARGC1A sits on the minus strand of chromosome 4, so the plus-strand C allele corresponds to a G on the coding strand. The T (reference) and C (alternate) alleles at this position may differentially affect miRNA binding site integrity or RNA-binding protein recognition, with potential consequences for PPARGC1A mRNA stability and the amount of PGC-1alpha protein produced in metabolically active tissues including skeletal muscle, adipose tissue, and liver.

Lower PGC-1alpha expression — if the C allele does reduce it — would impair mitochondrial biogenesis capacity, reduce the rate of fat oxidation at rest and during exercise, and compromise insulin sensitivity in muscle. Conversely, the T allele would maintain normal or higher PGC-1alpha output.

The Evidence

No published studies have directly examined rs2279525 in human metabolic phenotype data. The evidence for this entry rests on three well-established foundations:

First, the established biology of PGC-1alpha³³ established biology of PGC-1alpha
Liang and Ward. PGC-1alpha: a key regulator of energy metabolism. Adv Physiol Educ, 2006. PPARGC1A is a causally important gene for mitochondrial metabolism. Its expression is strongly downregulated in muscle of insulin-resistant and obese individuals compared to insulin-sensitive matched controls, and the gene's variants reliably associate with energy metabolism phenotypes.

Second, functional studies of nearby PPARGC1A variants confirm that this gene's expression level is causally linked to adipocyte biology. Mudry et al., 2023⁴⁴ Mudry et al., 2023
Mudry et al. Engineered allele substitution at PPARGC1A rs8192678 alters human white adipocyte differentiation, lipogenesis, and PGC-1alpha content and turnover. Diabetologia, 2023 used isogenic human cell lines to show that the C allele of rs8192678 (Gly482Ser) reduces PPARGC1A mRNA levels and PGC-1alpha protein content in white adipocytes, with downstream effects on lipogenesis and adipocyte differentiation. This directly demonstrates that PPARGC1A expression level is causally important.

Third, meta-analytic evidence⁵⁵ meta-analytic evidence
Bhat et al. Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia, 2005 for the better-characterized Gly482Ser variant (rs8192678) — a missense change in the same gene — establishes the gene as a modest but consistent contributor to T2D risk across large populations (OR 1.07 per Ser allele, P = 0.04, 8 studies, ~8,500 individuals).

The 3' UTR location of rs2279525 is biologically plausible for regulatory effects, but the variant's specific functional impact and effect size on human metabolic phenotypes remain uncharacterized. This is an emerging evidence entry.

Practical Actions

Because no direct human metabolic data exist for this variant, practical guidance derives from PPARGC1A biology generally. Supporting PGC-1alpha expression through aerobic training is the most evidence-anchored strategy: zone 2 aerobic training (sustained effort at 60-70% of maximum heart rate) is among the strongest physiological stimuli for PPARGC1A upregulation in muscle and adipose tissue. For those with the C allele — where mRNA stability may be subtly reduced — structured aerobic conditioning is particularly important for maintaining mitochondrial density.

Ubiquinol CoQ10⁶⁶ Ubiquinol CoQ10
coenzyme Q10 in its pre-reduced form: more bioavailable than the standard ubiquinone form and directly supports the mitochondrial electron transport chain at 100–200 mg daily provides direct substrate for the mitochondrial machinery that PPARGC1A builds, offering a targeted complement to training for those with potential PPARGC1A regulatory variants.

Interactions

rs2279525 is in the same gene as the better-characterized PPARGC1A variants rs8192678 (Gly482Ser) and rs4235308 (intronic). These three variants act at different levels: rs8192678 alters the PGC-1alpha protein directly; rs4235308 may affect intronic regulation; rs2279525 may affect 3' UTR mRNA stability. Combined carriership of multiple PPARGC1A regulatory variants has not been studied, but compounded reduction in PGC-1alpha output is biologically plausible. PPARG itself (rs1801282 Pro12Ala) is the nuclear receptor that PGC-1alpha coactivates — variants in both could compound deficits in adipose tissue insulin sensitivity.

The FADS gene cluster on chromosome 11 contains dozens of variants that affect how efficiently your body converts short-chain dietary fats into long-chain polyunsaturated fatty acids (LC-PUFAs) such as arachidonic acid, EPA, and DHA. Most of these variants travel together in a single large block of linkage disequilibrium¹¹ linkage disequilibrium
A genomic region where specific allele combinations are inherited together more often than expected by chance; variants in one LD block are effectively surrogates for each other. rs2524299 is notable because it does not belong to that primary block. It sits within a distinct regulatory region of FADS2 intron 1 — what researchers call Block 2 — and captures an independent regulatory signal that is not covered by the other FADS2 variants already on the platform (rs174568 and rs174575).

The Mechanism

rs2524299 is one of ten SNPs defining the Block 2 haplotype in FADS2 intron 1, a conserved locus containing predicted binding sites for SREBP and PPARγ²² SREBP and PPARγ
Sterol regulatory element binding protein and peroxisome proliferator-activated receptor gamma — two transcription factors that regulate lipid and fatty acid metabolism. Carriers of the minor haplotype (tagged by the T allele at rs2524299) show lower basal expression of both FADS1 and FADS2 in liver tissue. Because FADS2 encodes delta-6 desaturase (D6D) — the rate-limiting enzyme that initiates conversion of linoleic acid (LA) to gamma-linolenic acid (GLA), and alpha-linolenic acid (ALA) to stearidonic acid (SDA) — reduced expression compresses both the omega-6 and omega-3 elongation pathways simultaneously.

The result is the same substrate-product inversion seen across the FADS cluster: T allele carriers accumulate short-chain precursors (LA, ALA) while producing less of the long-chain end-products (arachidonic acid, EPA, DHA) for a given dietary intake.

Importantly, this Block 2 haplotype is not in linkage disequilibrium with the primary FADS cluster haplotype³³ this Block 2 haplotype is not in linkage disequilibrium with the primary FADS cluster haplotype
Meaning that rs2524299 and rs174568 or rs174575 can be inherited independently; a person can carry both risk haplotypes simultaneously, or the Block 2 risk allele without the primary FADS risk allele. This independence means rs2524299 provides additive information about FADS2 regulation beyond what the other FADS2 variants in the database capture.

The Evidence

rs2524299 was examined alongside five other common FADS polymorphisms in the Costa Rica Study of fatty acid desaturase gene variants and myocardial infarction⁴⁴ Costa Rica Study of fatty acid desaturase gene variants and myocardial infarction
Aslibekyan et al. 2012, Front Genet — 1,756 Costa Rican adults in a matched case-control design, with replication in the Nurses' Health Study and Health Professionals Follow-Up Study. Genetic variation across the FADS cluster — including rs2524299 — was associated with a robust linear decrease in adipose gamma-linolenic acid, arachidonic acid, and eicosapentaenoic acid. The minor allele consistently predicted lower concentrations of these long-chain products in adipose tissue fatty acid profiles.

An earlier Costa Rica Study analysis by Baylin et al. 2007⁵⁵ Baylin et al. 2007
alpha-Linolenic acid, Delta6-desaturase gene polymorphism, and the risk of nonfatal myocardial infarction; Am J Clin Nutr examined 1,694 case-control pairs and found that FADS2 intron/promoter variants in this region were associated with lower adipose EPA and arachidonic acid, consistent with impaired ALA-to-EPA conversion. The intron 1 regulatory locus was specifically associated with variation in delta-6 desaturase activity.

The functional architecture of this regulatory locus was characterized by Reardon et al. 2012⁶⁶ Reardon et al. 2012
Insertion-Deletions in a FADS2 Intron 1 Conserved Regulatory Locus Control Expression of Fatty Acid Desaturases 1 and 2 and Modulate Response to Simvastatin; Prostaglandins Leukot Essent Fatty Acids, which showed that the Block 2 haplotype (containing rs2524299) controls basal expression of both FADS1 and FADS2 in liver cells. Minor haplotype homozygotes showed significantly lower basal FADS1 expression and, paradoxically, 20–40% greater upregulation of FADS1 and FADS2 in response to simvastatin — suggesting this locus participates in statin-mediated lipid regulation.

The broader evidence base for FADS cluster variants affecting LC-PUFA synthesis was confirmed in a systematic review of 132 studies including ~500,000 participants⁷⁷ systematic review of 132 studies including ~500,000 participants
Visioli et al. 2026, Food Funct, showing that minor allele carriers across the FADS cluster show approximately 40–60% lower LC-PUFA conversion efficiency, with 14 studies demonstrating significant gene-by-diet interactions.

Practical Actions

For T allele carriers at rs2524299, the practical implication mirrors the other FADS2 impaired-conversion genotypes: plant-based omega-3 sources (flaxseed, chia, walnuts) supply ALA, but the first conversion step — ALA to stearidonic acid via FADS2 — is reduced by this haplotype. Preformed EPA and DHA from marine or algae-based sources bypass the impaired step entirely. TT homozygotes (the most impaired group, ~3% globally but ~17% in East Asian populations) should prioritize 2–4 g combined EPA+DHA daily; AT heterozygotes benefit from 1–2 g daily.

One clinically relevant interaction with medications: carriers of the Block 2 minor haplotype show enhanced FADS1 and FADS2 upregulation in response to statins and LXR agonists. This suggests that statin therapy may partially compensate for the reduced basal desaturase expression in this genotype — though this finding is preliminary and does not change the core supplementation strategy.

Interactions

rs2524299 is in linkage disequilibrium with rs2727270 and rs2727271 (Block 2 haplotype partners) but is independent of rs174568 and rs174575 (the primary FADS2 LD block). A person carrying T alleles at both rs2524299 and T alleles at rs174568 or rs174575 faces additive impairment of FADS2 expression from two independent regulatory mechanisms — a situation that would produce more severe LC-PUFA deficiency than either variant alone. Check related SNPs rs174568 and rs174575 for a full picture of your FADS2 regulatory status.

FOXO3 is one of only two genes replicated for longevity associations across every human population tested—the other is APOE. Within FOXO3's vast 101,625 base-pair second intron, several variants independently contribute to exceptional lifespan. rs2764264 is the third major longevity signal in this region, alongside rs2802292 and rs13217795, and has been replicated across Japanese, Italian, German, Chinese, and Northern European populations.

The original 2008 discovery¹¹ The original 2008 discovery
Willcox BJ et al. FOXO3A genotype is strongly associated with human longevity. Proc Natl Acad Sci USA. 2008 identified rs2764264, rs2802292, and rs13217795 together as longevity variants in Japanese American men. Subsequent meta-analysis and centenarian studies have confirmed each variant carries independent statistical weight, though their effects are partially correlated through a shared haplotype.

The Mechanism

rs2764264 sits in FOXO3 intron 2 and operates through a distinct mechanism from its better-studied neighbors. While rs2802292 creates an HSF1 activator binding site that upregulates FOXO3 during cellular stress, rs2764264 is predicted (by computational transcription factor binding site analysis) to disrupt an NKX3 transcription factor binding site . NKX3-1 is a homeobox protein involved in controlling cell proliferation and differentiation. When NKX3 can bind—which occurs in individuals with the T allele—it likely functions as a transcriptional repressor at this intronic element. The protective C allele abolishes this binding site, removing a brake on FOXO3 expression.

The result is complementary but mechanistically distinct from rs2802292: where rs2802292 adds a stress-activated accelerator, rs2764264 removes a constitutive repressor. Together—and with the broader FOXO3 longevity haplotype—these variants may cooperate to keep FOXO3 expression higher across a wider range of cellular contexts.

No proxies in complete linkage disequilibrium with rs2764264 have been identified, confirming this variant captures an independent regulatory element within the FOXO3 locus.

The Evidence

A meta-analysis of 11 independent case-control studies²² A meta-analysis of 11 independent case-control studies
Bao J et al. Association between FOXO3A gene polymorphisms and human longevity: a meta-analysis. Asian J Androl. 2014 synthesized 1,959 long-lived cases and 1,621 controls across diverse populations, finding the C allele significantly associated with longevity (OR = 1.20, 95% CI 1.04–1.37, P = 0.01) . Crucially, sex-stratified analysis revealed a male-specific effect: OR = 1.38 (95% CI 1.15–1.66, P = 0.001) in males, with no significant association in females (OR = 0.93, P = 0.508) , marking rs2764264 as a male-enriched longevity signal.

Analysis across four major centenarian cohorts³³ Analysis across four major centenarian cohorts
Bae H et al. Effects of FOXO3 Polymorphisms on Survival to Extreme Longevity in Four Centenarian Studies. J Gerontol A Biol Sci Med Sci. 2018 confirmed the effect in independent datasets, with the C allele showing coded allele frequency of 0.47 in extreme survivors versus 0.37 in controls (β = 0.15, SE = 0.042, P = 4.15×10⁻⁴). The Southern Italian cohort showed the strongest signal (β = 0.46, P = 0.0019).

The practical significance becomes especially clear in men with age-related disease. A prospective study in 3,584 elderly Japanese American men (1991–2019)⁴⁴ A prospective study in 3,584 elderly Japanese American men (1991–2019)
Chen R et al. FOXO3 longevity genotype mitigates the increased mortality risk in men with a cardiometabolic disease. Aging. 2020 found that the FOXO3 longevity haplotype—including rs2764264—conferred HR = 0.81 (95% CI 0.72–0.91, P = 0.0002) for all-cause mortality in men with cardiometabolic disease (diabetes, hypertension, or coronary heart disease) . Most remarkably, men with cardiometabolic disease who carried the longevity haplotype had essentially identical survival to men without any cardiometabolic disease—the genetic variants fully offset the excess mortality risk of these conditions.

Practical Implications

The male specificity of rs2764264's longevity association distinguishes it from rs2802292, whose protective effects appear in both sexes. Men carrying the T allele lack the NKX3-site disruption that removes constitutive repression of FOXO3, and therefore may have modestly lower FOXO3 expression in resting (non-stressed) cellular conditions.

FOXO3 expression is highly modifiable through lifestyle. Intermittent fasting, high-intensity exercise, caloric restriction, and cold exposure all activate FOXO3 pathways. These interventions may be particularly valuable for TT men, compensating for the lower baseline FOXO3 drive associated with the intact NKX3 binding site. The cardiometabolic disease data suggests that metabolic health is the domain where this variant's effects are most consequential—making metabolic monitoring and early intervention especially important for TT men who develop diabetes, hypertension, or coronary disease.

Interactions

rs2764264 is part of a longevity haplotype in FOXO3 intron 2 alongside rs2802292, rs13217795, and rs2802288. While these variants are correlated (particularly in East Asian populations), rs2764264 is unique in having no variant in complete LD, meaning it captures regulatory information not fully tagged by any of its neighbors. The NKX3-site mechanism is distinct from the HSF1-activator mechanism of rs2802292 and from the isoform-splicing mechanism of rs13217795, suggesting these three variants affect FOXO3 expression through complementary pathways.

For men who carry the TT genotype at both rs2764264 and rs2802292, the combined reduction in FOXO3 regulatory capacity may be greater than either variant alone—a potential compound interaction that warrants study.

The FKRP gene encodes fukutin-related protein¹¹ fukutin-related protein
A Golgi-resident enzyme that adds sugar molecules to alpha-dystroglycan, a key protein linking muscle fibers to the surrounding extracellular matrix, a glycosyltransferase enzyme that modifies the surface of muscle fiber membranes. The c.826C>A mutation (L276I) substitutes leucine with isoleucine at amino acid position 276, partially disrupting this enzyme's function. In the autosomal recessive inheritance pattern, two copies of the risk allele are needed to cause disease — but single-copy carriers are clinically important for reproductive counseling.

This variant is a European founder mutation: the same ancestral chromosomal haplotype has been identified in patients of European descent across the UK, Germany, Scandinavia, North America, and Brazil, suggesting a single common ancestor. It is essentially absent from East Asian and South Asian populations. In Northern European cohorts such as Norway, the population prevalence of LGMD R9²² population prevalence of LGMD R9
Limb-girdle muscular dystrophy R9, previously called LGMD2I — R9 refers to the FKRP gene in the revised 2017 nomenclature reaches 2.84 per 100,000, the highest reported worldwide.

The Mechanism

FKRP normally catalyses the transfer of ribitol-5-phosphate onto the O-mannosyl glycan chain³³ O-mannosyl glycan chain
A chain of sugar molecules attached to serine or threonine residues on alpha-dystroglycan via oxygen linkage of alpha-dystroglycan (α-DG). This glycan chain is the molecular "glue" that lets muscle fibers attach to laminin and other proteins in the extracellular matrix. Without proper glycosylation, the muscle membrane is structurally fragile and tears during repeated contraction cycles, triggering progressive degeneration and fibrosis.

The L276I mutation reduces but does not abolish FKRP enzyme activity. This partial loss explains why homozygous carriers typically develop a milder, later-onset muscular dystrophy compared to patients with FKRP null alleles (frameshift or nonsense mutations), who can present with severe Walker-Warburg syndrome in infancy. In the mouse model⁴⁴ mouse model
Krag TO & Vissing J. A New Mouse Model of Limb-Girdle Muscular Dystrophy Type 2I Homozygous for the Common L276I Mutation. J Neuropathol Exp Neurol, 2015, homozygous L276I mice show a 78% reduction in α-DG glycosylation by 20 months, accompanied by progressive fibrosis and myopathy — faithfully mirroring the human disease.

The Evidence

The Global FKRP Registry⁵⁵ Global FKRP Registry
Murphy LB et al. Global FKRP Registry: Observations in More Than 300 Patients with Limb Girdle Muscular Dystrophy R9. Ann Clin Transl Neurol, 2020 analysed 305 genetically confirmed LGMD R9 patients: 67.9% were homozygous for c.826C>A, 28.5% compound heterozygous. Among the cohort, 75.1% remained ambulant at time of enrollment, and 23.2% had documented cardiac impairment.

A Norwegian national cohort study⁶⁶ Norwegian national cohort study
Jensen SM et al. Epidemiology and Natural History in 101 Subjects with FKRP-Related Limb-Girdle Muscular Dystrophy R9. Neuromuscular Disorders, 2023 of 101 patients found that 88% were homozygous for c.826C>A. Disease showed a bimodal age-of-onset distribution, and one-third of patients developed respiratory insufficiency before losing ambulation. Cardiomyopathy correlated with male sex but not with age or functional stage.

A dedicated cardiomyopathy study⁷⁷ cardiomyopathy study
Libell EM et al. Cardiomyopathy in Limb Girdle Muscular Dystrophy R9, FKRP Related. Muscle Nerve, 2020 of 56 LGMD R9 patients found cardiomyopathy in 45% overall. Among those homozygous for c.826C>A, the median age at cardiomyopathy onset was 54.2 years — substantially later than patients carrying other, more severe FKRP mutations (median 18.1 years). This genotype-specific timeline is clinically meaningful for structuring cardiac surveillance programs.

Practical Actions

Homozygous AA carriers require regular cardiac screening (echocardiogram and ECG at diagnosis, then every 2–3 years), pulmonary function monitoring, and referral to a neuromuscular specialist for management of progressive proximal muscle weakness. Physical therapy focused on maintaining ambulation and respiratory muscle strength should begin proactively. Gene therapy trials are actively ongoing — enrolling in a clinical trial registry⁸⁸ clinical trial registry
ClinicalTrials.gov FKRP gene therapy trials is appropriate.

Heterozygous CA carriers do not develop disease themselves but carry a 50% per-pregnancy chance of passing the risk allele. When both reproductive partners are carriers, each pregnancy has a 25% chance of producing an affected (AA) child. Preconception genetic counseling and, if desired, preimplantation genetic testing (PGT-M) are clinically appropriate options.

Interactions

No compound heterozygosity interactions are captured here for L276I specifically, since the disease mechanism requires homozygosity or trans-compound heterozygosity with a second FKRP pathogenic allele. Other FKRP variants that can compound with L276I in trans to cause LGMD R9 include deletion/frameshift mutations in FKRP that individually cause more severe phenotypes (Walker-Warburg syndrome). Compound heterozygotes with one c.826C>A allele and one severe allele typically present with an intermediate phenotype, more severe than homozygous L276I but milder than homozygous null alleles.

C-reactive protein (CRP) is the liver's first responder to inflammatory signals. Under normal conditions it circulates at low concentrations, but during acute infection or tissue injury it can surge more than 1,000-fold within hours. What's less appreciated is that baseline CRP — the level you carry when healthy — is strongly heritable, with genetic factors explaining 30–40% of variation¹¹ genetic factors explaining 30–40% of variation
Twin and family studies estimate heritability of basal CRP at 30–40%. The rs3093059 variant sits directly in the CRP gene promoter and is one of the most functionally validated of all CRP genetic regulators.

The Mechanism

rs3093059 is located approximately 757 base pairs upstream of the CRP transcription start site (papers describe it as −757T>C; on the genomic plus strand the alleles are A and G, with G being the CRP-elevating variant). This position falls within a functional E-box element (E-box 3) in the promoter. E-boxes are short DNA sequences (CANNTG) that recruit basic helix-loop-helix transcription factors such as USF1 and USF2; these factors are major drivers of CRP gene expression in hepatocytes.

Danik et al. demonstrated directly in promoter constructs that rs3093059 disrupts transcription factor binding within E-box 3, altering transcriptional activity and producing measurable differences in baseline serum CRP²² Danik et al. demonstrated directly in promoter constructs that rs3093059 disrupts transcription factor binding within E-box 3, altering transcriptional activity and producing measurable differences in baseline serum CRP
Functional study with promoter reporter assays confirming E-box disruption (PMID 15778807). The G allele strengthens E-box binding affinity, increasing basal CRP expression. This is a cis-acting effect — the variant acts on the same chromosome's CRP gene — and accounts for up to 1.14% of variance in hsCRP concentrations³³ up to 1.14% of variance in hsCRP concentrations
Contribution to hsCRP variance across multiple cohorts, comparable in magnitude to the more frequently cited rs1205 3′ UTR variant.

The Evidence

The CRP-elevating effect of rs3093059 is among the most consistently replicated findings in inflammation genetics.

Crawford et al. conducted a comprehensive survey of CRP promoter variation in European American and African American adults, finding rs3093059 among the SNPs most strongly associated with plasma CRP levels across large cardiovascular cohorts⁴⁴ Crawford et al. conducted a comprehensive survey of CRP promoter variation in European American and African American adults, finding rs3093059 among the SNPs most strongly associated with plasma CRP levels across large cardiovascular cohorts
Multi-cohort association study (PMID 15897982). In the NHLBI Family Heart Study, rs3093059 was significantly associated with CRP (P = 0.0004), and the association replicated in the Women's Health Study, the Pravastatin Inflammation/CRP Evaluation trial, and the Physicians' Health Study.

In a prospective Shanghai cohort of 2,000 unrelated Han Chinese adults, the minor G allele of rs3093059 was significantly associated with elevated circulating CRP (P < 0.001) and with incident essential hypertension (OR per CRP quartile 1.64; 95% CI 1.18–2.26)⁵⁵ the minor G allele of rs3093059 was significantly associated with elevated circulating CRP (P < 0.001) and with incident essential hypertension (OR per CRP quartile 1.64; 95% CI 1.18–2.26)
908 hypertensives, 1,092 normotensives with 2-year follow-up (PMID 22763479). This links genetically elevated CRP, via rs3093059, to downstream vascular risk.

In a large elderly Chinese cohort (RuLAS, n=1,723), rs3093059 was significantly associated with serum CRP levels (β = 0.222, P < 0.001)⁶⁶ rs3093059 was significantly associated with serum CRP levels (β = 0.222, P < 0.001)
Rugao Longevity and Ageing Study (PMID 27016573), with CRP levels increasing in a dose-dependent fashion with G allele count.

For cardiovascular outcomes, a meta-analysis of 9 case-control studies (2,992 MI patients, 4,711 controls) found rs3093059 associated with decreased MI risk, especially in Asian populations⁷⁷ meta-analysis of 9 case-control studies (2,992 MI patients, 4,711 controls) found rs3093059 associated with decreased MI risk, especially in Asian populations
Zhu et al. meta-analysis (PMID 24010569). This apparent paradox — a CRP-raising allele associated with lower MI risk in some populations — reflects the complexity of CRP's role as both biomarker and potentially active participant in vascular biology, as well as linkage disequilibrium with other CRP haplotype variants that have protective effects.

For stroke, a prospective Han Chinese cohort found rs3093059 independently predicted poor 3-month outcome after first-ever large-artery atherosclerotic ischemic stroke (dominant model OR 2.49; 95% CI 1.55–4.00; recessive model OR 3.67; 95% CI 1.22–11.03)⁸⁸ rs3093059 independently predicted poor 3-month outcome after first-ever large-artery atherosclerotic ischemic stroke (dominant model OR 2.49; 95% CI 1.55–4.00; recessive model OR 3.67; 95% CI 1.22–11.03)
Nanjing Stroke Registry (PMID 29556980).

A haplotype analysis in Chinese Han subjects (730 T2DM cases, 765 controls) found that the CGCA haplotype — which includes the A (reference/non-risk) allele at rs3093059 — was associated with decreased type 2 diabetes risk (OR 0.83; 95% CI 0.68–0.98; P = 0.047)⁹⁹ haplotype analysis in Chinese Han subjects (730 T2DM cases, 765 controls) found that the CGCA haplotype — which includes the A (reference/non-risk) allele at rs3093059 — was associated with decreased type 2 diabetes risk (OR 0.83; 95% CI 0.68–0.98; P = 0.047)
Haplotype analysis (PMID 38833006), further illustrating how this CRP locus sits at the intersection of inflammation, metabolic disease, and cardiovascular risk.

Practical Implications

Elevated basal CRP independently predicts all-cause mortality, cardiovascular events, and stroke risk across multiple population studies. The rs3093059 G allele contributes to constitutively higher CRP by increasing hepatic CRP gene transcription. This matters most when combined with environmental factors (obesity, poor diet, smoking, sedentary lifestyle) that further amplify inflammatory load.

Because CRP is a modifiable biomarker, G allele carriers have both an elevated baseline and actionable targets. High-sensitivity CRP (hs-CRP) testing provides a direct readout of how much your environment is amplifying your genetic set point: values below 1 mg/L indicate low cardiovascular inflammatory risk, 1–3 mg/L moderate risk, and above 3 mg/L high risk. Omega-3 fatty acids (EPA/DHA) reduce hs-CRP by 0.3–0.5 mg/L on average across RCTs; statins lower CRP independently of LDL by 15–25%; and weight loss produces approximately 0.13 mg/L reduction per kilogram lost.

Interactions

rs3093059 exists in strong linkage disequilibrium with three other CRP gene variants — rs1205, rs1800947, and rs2794521 — which together define major CRP expression haplotypes. The CGCA haplotype (rs1205-C, rs1130864-G, rs2794521-C, rs3093059-A) is associated with decreased type 2 diabetes risk, suggesting that haplotype context can modify the metabolic consequences of any single CRP variant. A user carrying rs3093059 AG or GG should also review their rs1205 and rs1800947 results to understand their full CRP haplotype.

The rs3093059 effect on stroke outcome (PMID 29556980) was significant after adjusting for baseline CRP, blood pressure, and other covariates, suggesting it may have effects beyond simply raising CRP — possibly through local promoter regulation affecting CRP's acute-phase response dynamics during cerebrovascular events.

Every heartbeat depends on myosin motors pulling actin filaments with exquisite precision. The regulatory myosin light chain — encoded by MYL2 — wraps around the myosin neck like a molecular clamp, stiffening the lever arm and fine-tuning the speed and force of each contraction stroke. rs397516407 (c.488A>C, p.Glu163Ala) replaces a negatively charged glutamic acid with a neutral, non-polar alanine at position 163 of this 166-amino-acid protein — [a non-conservative substitution | glutamic acid carries a negative charge; alanine is neutral and non-polar; this difference can disrupt calcium-sensitive conformational switches] in the C-terminal EF-hand-like domain. The variant is absent from all large population databases (gnomAD, 1000 Genomes) and appears exclusively in hypertrophic cardiomyopathy (HCM) families, earning a "likely pathogenic / pathogenic" classification from multiple clinical laboratories including Invitae and the Laboratory for Molecular Medicine (ClinVar VCV000043480).

The Mechanism

MYL2 belongs to the [EF-hand superfamily | calcium-binding proteins with a characteristic helix-loop-helix fold; the MYL2 C-terminal EF-hand modulates how the protein responds to intracellular calcium changes during systole and diastole]. Position 163 sits within the fourth EF-hand pair, adjacent to Asp166 — a residue whose substitution (D166V) has independently been shown to impair calcium binding affinity and disrupt sarcomeric force generation. [Sheikh et al., 2015 | Sheikh F, Lyon RC, Chen J. Functions of myosin light chain-2 (MYL2) in cardiac muscle and disease. Gene. 2015;569(1):14-20. https://pubmed.ncbi.nlm.nih.gov/26074085/¹¹ https://pubmed.ncbi.nlm.nih.gov/26074085/]

When the MYL2–myosin interaction is perturbed by a missense in this domain, myosin heads spend more time in the force-generating (on) state relative to the resting (off) state — a hallmark of sarcomeric HCM. The result is hypercontractility, impaired relaxation, and a remodelling cascade: the ventricular wall thickens, becomes stiffer, and can obstruct outflow. Over years this [diastolic dysfunction | impaired filling of the heart between beats, even while pumping strength is preserved or increased] drives breathlessness, fatigue, and elevated arrhythmia risk.

The Evidence

MYL2 variants account for 1–3% of all familial HCM cases — a small fraction, but with disproportionate clinical impact because MYL2 mutations can cause both benign and malignant phenotypes. [Flavigny et al., 1998 | Flavigny J et al. Identification of two novel mutations in the ventricular regulatory myosin light chain gene (MYL2) associated with familial and classical forms of hypertrophic cardiomyopathy. J Mol Med. 1998;76:208–214. https://pubmed.ncbi.nlm.nih.gov/9535554/²² https://pubmed.ncbi.nlm.nih.gov/9535554/]

The pathogenic p.Glu163Ala substitution (along with the related p.Glu163Gly at the same codon) is absent from gnomAD across all ancestries, strongly supporting disease causation rather than benign polymorphism. An adjacent variant, p.Gly162Glu (one residue N-terminal to Glu163), was studied by [Renaudin et al., 2018 | Renaudin P et al. A Novel Missense Mutation p.Gly162Glu of the Gene MYL2 Involved in Hypertrophic Cardiomyopathy: A Pedigree Analysis of a Proband. Mol Diagn Ther. 2018;22:219–223. https://pubmed.ncbi.nlm.nih.gov/29549657/³³ https://pubmed.ncbi.nlm.nih.gov/29549657/] in a 27-member pedigree: 12 of 16 carriers developed overt HCM; zero of 11 non-carriers had cardiomyopathy. This near-perfect segregation at the codon 162–163 region is direct functional evidence that mutations here are causally linked to HCM.

MYL2 penetrance is variable and context-dependent. A large meta-analysis of cascade-screened families found that pooled penetrance across sarcomere genes was 57% (95% CI 52–63%), with mean age at HCM diagnosis of 38 years. [Pelliccia et al., 2024 | Meta-Analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy. Circulation. 2024. https://pubmed.ncbi.nlm.nih.gov/37929589/⁴⁴ https://pubmed.ncbi.nlm.nih.gov/37929589/] Importantly, penetrance in MYL2 carriers rises sharply with co-existing hypertrophy triggers: in a Dutch cohort carrying MYL2 p.Glu22Lys, penetrance reached 89% when hypertension or obesity was present, versus 36% in carriers without additional risk factors. [Claes et al., 2016 | https://pubmed.ncbi.nlm.nih.gov/26497160/⁵⁵ https://pubmed.ncbi.nlm.nih.gov/26497160/] Controlling modifiable risk factors is therefore a meaningful lever for gene-positive individuals.

Practical Actions

Heterozygous carriers should have baseline and serial cardiac evaluation: echocardiography or cardiac MRI to detect left ventricular hypertrophy, 12-lead ECG and 24–48 hour Holter monitoring for arrhythmia, and cardiology review. Consistent with the 2024 AHA/ACC guideline for HCM management, cascade testing of all first-degree relatives is strongly recommended when a pathogenic or likely pathogenic sarcomere variant is confirmed. [AHA/ACC 2024 | https://pubmed.ncbi.nlm.nih.gov/38718139/⁶⁶ https://pubmed.ncbi.nlm.nih.gov/38718139/] Blood pressure should be kept in the optimal range: hypertension substantially amplifies penetrance in MYL2 carriers.

Interactions

The Glu163 codon also has a second clinically relevant alternate allele: T>C on the plus strand produces p.Glu163Gly (ClinVar VCV000181421), classified as likely pathogenic by GeneDx. Compound heterozygosity at this locus (Glu163Ala + Glu163Gly) would be mechanistically significant but is not reported in the literature — carriers of either allele should be assessed individually by a cardiologist. MYL2 pathogenic variants interact additively with hypertension (the most important co-modifier in published cohorts) and with other sarcomere-gene variants; anyone carrying a second sarcomere mutation is at substantially higher risk and warrants expedited specialist referral.

ABCA1 (ATP-binding cassette transporter A1)¹¹ ABCA1 (ATP-binding cassette transporter A1)
ABCA1 is a large transmembrane protein that pumps cholesterol and phospholipids out of cells and transfers them to apolipoprotein A-I (apoA-I), the founding step of reverse cholesterol transport is the molecular gatekeeper for HDL biogenesis. Without functional ABCA1, nascent HDL particles cannot form, and excess cellular cholesterol accumulates rather than being transported back to the liver for excretion. This is illustrated dramatically by Tangier disease, a rare condition caused by biallelic loss-of-function mutations in ABCA1 that results in near-absent HDL and massive tissue cholesterol deposits.

rs4149274 is a common intronic variant within ABCA1 on chromosome 9q31. The A allele (plus-strand notation; the coding-strand complement is T) has been associated with modestly lower HDL-cholesterol concentrations in GWAS studies, while the G allele (reference, ~70% frequency in Europeans) is associated with normal to slightly higher HDL levels. Approximately 42% of people carry one A allele (AG genotype) and about 9% carry two (AA).

The Mechanism

ABCA1 is located on the minus (reverse) strand of chromosome 9. rs4149274 lies within an intron and does not alter the protein directly. Intronic variants can influence gene expression by disrupting transcription factor binding sites, splicing regulatory elements, or chromatin enhancer activity.

Research by Howard et al.²² Howard et al.
Howard AD et al. Allele-specific enhancers mediate associations between LCAT and ABCA1 polymorphisms and HDL metabolism. PLoS One, 2019 demonstrated that SNPs within ABCA1 introns reside in functional enhancer elements that loop to the ABCA1 promoter and show allele-specific differences in transcription factor (STAT3) binding and regulatory activity in liver-derived cell lines. This establishes a plausible mechanism: intronic A alleles may reduce the binding affinity of transcriptional activators, resulting in lower ABCA1 mRNA expression and consequently less cholesterol efflux to apoA-I — producing measurably lower circulating HDL.

The Evidence

The ABCA1 locus was among the most robustly replicated HDL-cholesterol associations in early lipid GWAS. Willer et al.³³ Willer et al.
Willer CJ et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet, 2008 confirmed ABCA1 among 11 previously implicated loci reaching genome-wide significance in a meta-analysis of ~8,816 individuals.

The most comprehensive evidence comes from Teslovich et al.⁴⁴ Teslovich et al.
Teslovich TM et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature, 2010, which pooled 46 GWAS scans in over 100,000 individuals of European ancestry, identifying 95 lipid-associated loci including ABCA1. The ABCA1 intronic tag SNP rs1883025 showed an effect of approximately −0.024 mmol/L (~−0.94 mg/dL) per A allele on HDL-C, with a p-value of ~1.75 × 10⁻³³. rs4149274 is in the same ABCA1 intronic region and likely tags an overlapping signal; the commonly reported effect is approximately 1.5 mg/dL per reference (G) allele.

Frikke-Schmidt et al.⁵⁵ Frikke-Schmidt et al.
Frikke-Schmidt R et al. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest, 2004 showed in a large Danish population study that both rare mutations and common SNPs in ABCA1 influence HDL-C levels, establishing that the gene contributes to HDL variation even outside the extreme phenotype of Tangier disease.

It is important to note that HDL level alone does not predict cardiovascular risk as simply as once assumed — Mendelian randomisation studies have shown that genetically low HDL does not uniformly predict increased ischemic heart disease risk⁶⁶ genetically low HDL does not uniformly predict increased ischemic heart disease risk
Frikke-Schmidt R. Genetic variation in ABCA1, HDL cholesterol, and risk of ischemic heart disease in the general population. Atherosclerosis, 2010. rs4149274's primary value lies in HDL-focused cardiovascular risk profiling rather than as a standalone risk marker.

Practical Actions

For AG heterozygotes, the modest reduction in HDL is worth monitoring over time as part of a standard lipid panel. Practical steps that specifically target ABCA1-mediated HDL production include: limiting dietary saturated fat (which competitively inhibits ABCA1-mediated efflux by altering membrane cholesterol pools), ensuring adequate niacin intake (a known ABCA1 upregulator in liver cells), and regular aerobic exercise which increases ABCA1 expression. However, the most actionable step is knowing your HDL trajectory through periodic measurement.

For AA homozygotes, the two-allele dose produces a more consistent HDL-lowering effect. Serum HDL-C monitoring, combined with assessment of HDL function (if available), and attention to dietary fat quality provide the most targeted approach to this genotype.

Interactions

ABCA1 variants interact functionally with APOA1 — the primary HDL scaffold protein that ABCA1 lipidates. Carriers of both ABCA1 intronic variants and APOA1 promoter variants may have compounded effects on nascent HDL formation. ABCA1 expression is upregulated by liver X receptor (LXR) agonists; dietary oxysterols and plant sterols that activate LXR may modulate the practical impact of this genotype. The CETP rs1800775 variant (which influences HDL catabolism) operates independently at the opposite end of the HDL lifecycle, making ABCA1 and CETP variants complementary rather than redundant in a cardiovascular risk profile.